Drugs / MT-2990
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06196905 | Jun 2024 → Jan 2026 | anti-neutrophil cytoplasmic antibody-associated vasculitis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03570957 | Jul → Dec 2018 | seasonal allergic rhinitis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03156738 | May → Dec 2017 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03840993 | Jan 2019 → May 2021 | endometriosis | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-28 | Tanabe Pharma Corporation | Tanabe Pharma Out-licenses MT-2990, a Fully human anti-IL-33 monoclonal antibody tanabe-pharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-2990 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06196905 ↗ |
| Route | Intravenous | “Subjects will receive a single IV dose of MT-2990” NCT03156738 ↗ |